Prevnar Supply Update Peter R. Paradiso, Ph.D. Wyeth Vaccines.

Slides:

Advertisements

Similar presentations

Target Product Profile and technical requirements Pre-tender Meeting Pneumococcal Vaccines under the AMC Unicef Supply Division, Copenhagen 26 August.

Advertisements

Prevnar 13™ Pneumococcal 13-valent conjugate vaccine

1 Vaccines and Related Biological Products Advisory Committee Meeting November 18, 2009 Prevnar 13 Pneumococcal 13-valent Conjugate Vaccine [Diphtheria.

Rotavirus vaccine impact. Introduction. Rotavirus vaccines lead to significant reductions in severe and fatal diarrhea in both vaccinated and unvaccinated.

Children Aged 5 to

An Approach to Demonstration of Effectiveness

2014 UPDATES FROM THE CDC’S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) William Schaffner, MD Professor of Preventive Medicine and Infectious Diseases.

Rotavirus Vaccine & Health Care Utilization for Diarrhea in U.S Children N Engl J Med 2011;365: Vanessa Craven Clinical Research Fellow.

Vaccines and Related Biological Products Advisory Committee Meeting

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.

Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.

Jan T. Poolman, Ph.D. Director, Bacterial Vaccines R&D

Various other updates Presented by: Karen S Ginsbury March

Vaccines and Related Biological Products Advisory Committee Meeting

Incidence of Influenza in Ontario Following the Universal Influenza Immunization Campaign Dianne Groll PhD, University of Ottawa David J Thomson PhD, Queen’s.

Impact of the Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease (IPD) in Ireland Data source: National Pneumococcal.

Basis for Developing a Pneumococcal Conjugate Vaccine for Adults George R. Siber, MD Executive Vice President and Chief Scientific Officer Wyeth Vaccines.

Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.

1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.

A program of the International Association of Immunization Managers Peer-to-Peer Exchange HPV Vaccination in Ireland Dr. Brenda Corcoran for Molly Howell,

The Changing Epidemiology of Acute Hepatitis A in Texas Rachel Wiseman, MPH, Lucille Palenapa, MS; Linda Gaul, PhD Emerging and Acute Infectious Disease.

© The Critical Thinking Consortium Children’s Rights – Caring adults # 1.

Prevention of pneumococcal disease – What are the prospects? Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Allison McGeer,

Harold S. Margolis, M.D. Division of Viral Hepatitis

Hib, Pneumo, Hep A and B MedCh 401 Lecture 4 19May06

The Impact of Racial and Ethnic Disparities in Influenza Vaccination on Minority Deaths Kevin Fiscella, MD, MPH Departments of Family Medicine Community.

Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.

State Affiliate Challenge 1 South Dakota School Nurses Association Florida Association of School Nurses Delaware School Nurse Association.

5th Annual Advocacy Project: ImmuneWise Section on Medical Students, Residents, and Fellowship Trainees

Decreasing Incidence of Pertussis in Massachusetts Following the Introduction of Tdap Noelle Cocoros, Nancy Harrington, Rosa Hernandez, Jennifer Myers,

Chris Knefelkamp, PharmD PGY2 Internal Medicine Resident Richard L. Roudebush VA Medical Center September 17, 2015 A SHOT IN THE DARK: PNEUMOCOCCAL PNEUMONIA.

Adult Immunization 2010 Pneumococcal Segment This material is in the public domain This information is valid as of May 25, 2010.

1 Vaccines and Related Biological Products Advisory Committee Meeting November 18, 2009 Questions for the Committee Prevnar 13 Pneumococcal 13-valent Conjugate.

1 Otitis Media Results from the Kaiser Permanente Efficacy Trial Steven Black, MD, Henry Shinefield, MD and Bruce Fireman, MS Kaiser Permanente Vaccine.

A Vaccine Supply Update For The U.S. Market A Presentation At The National Vaccine Advisory Committee Meeting June 3, 2003 Dean Mason Chief, Program Support.

1 |1 | Measles pre-elimination and resurgence in the African region Balcha Masresha IVD AFRO Global Measles Management Meeting Geneva March 2011.

Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines Vaccines and Related Biological Products Advisory Committee Meeting Lucia.

A Vaccine Supply Update For The U.S. Market A Presentation At National Advisory Committee Meeting February 4, 2003 Dean Mason Chief, Program Support Branch.

Pfizer’s Commitment to the Advance Market Commitment (AMC)

Update from the 2010 National Influenza Vaccine Summit meeting L.J Tan Co-chair, National Influenza Vaccine Summit Director, Medicine and Public Health,

Non-institutionalized adults vaccinated annually against influenza and ever vaccinated against pneumococcal disease. Healthy Kansans 2010 Steering Committee.

Pertussis and Pertussis Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.

Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:

Progress in adolescent vaccination coverage levels in the United States National Immunization Conference Washington, DC March 31, 2011 Shannon Stokley,

Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.

Ocean State Immunization Collaborative 2016 State - Supplied Vaccine Workshop May 17, 2016.

1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

Improving Pneumococcal Vaccination Rates David Diamant MD, Molly Benedum MD Center for Family Medicine Aim The aim is to increase awareness of pneumococcal.

Where Has All the Pertussis Gone? Pertussis Trends from and the Potential Early Impact of Tdap Vaccination National Immunization Conference Dallas,

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory.

Evaluation of the 2004 pneumococcal conjugate vaccine shortage utilizing data from the Michigan Childhood Immunization Registry Norma Allred, PhD, John.

Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010 Koh Cheng Thoon, Chia Yin Chong,

Pengjun Lu, PhD, MPH;1 Kathy Byrd, MD, MPH;2

Vaccines and Related Biological Products Advisory Committee Meeting

Ontario’s Pneumococcal Vaccination Program Allison McGeer

What’s new in 2010? (cont) New PCV 13 recommendations

The State of Pneumococcal Disease Prevention

Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia

Pneumococcal Disease Prevention in Children: Issues in the Era of PCVs

Addressing Pneumococcal Disease in Latino Communities

Daniel M. Musher, MD Mayo Clinic Proceedings

Changes in Streptococcus pneumoniae serotypes causing invasive disease with non- universal vaccination coverage of the seven-valent conjugate vaccine

Clinical Microbiology and Infection

MenB Update: Communicating the Imperative With Parents

National Immunization Conference

School-Based Immunization for Control of Influenza?

Presentation transcript:

Prevnar Supply Update Peter R. Paradiso, Ph.D. Wyeth Vaccines

Prevnar Supply Update As of April 21, 2003… Prevnar is out of backorder!

010203

Source: SDI Vaccination Audit March 2003 n=2,

Annual Incidence of Invasive Pneumococcal Disease in Vaccinated and Unvaccinated Children (NCKP) April 1996 – March 2002 Vaccine Serotypes <2 yr <1 yr <5 yr Prevnar Licensed

Rate After April 00-Mar 02 Cases/100,000 p-y < % (10, 26)11.37All > 5 yo % (2, 25) % (-3, 30) < % (41, 71) % (-27, 48) P-value Percent Reduction (95% CI) Rate Prior April 95- Mar 00 Cases/100,000 p-y Age Group (yrs) Impact of the Use of Prevnar ® in Children on Invasive Pneumococcal Disease in Older Children & Adults

Factors Effecting Vaccine Supply: Solutions For Manufacturers Create redundancies in critical manufacturing pathways (e.g. fill/finish) Be diligent in compliance updates (e.g. anticipate change)

Factors Effecting Vaccine Supply: Solution For users/purchasers Recognize value: it will lure manufacturers Create redundancies (e.g. stock piles) Pay attention to liability issues – emphasize the benefits (healthcare and cost)

Source: SDI Vaccination Coverage Audit Prevnar Supply Update Prevnar Vaccination Coverage (Infant Series) Backorder exceeds 1.0 million doses